Drug Profile


Alternative Names: CS 505

Latest Information Update: 01 May 2006

Price : $50

At a glance

  • Originator Daiichi Sankyo Inc; Kyoto Pharmaceutical Industries
  • Developer Daiichi Sankyo Europe; Daiichi Sankyo Inc
  • Class Antihyperlipidaemics; Indoleacetic acids; Small molecules
  • Mechanism of Action Sterol O-acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Hyperlipidaemia

Most Recent Events

  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
  • 26 Oct 2005 Discontinued - Phase-II/III for Hyperlipidaemia in Europe (PO)
  • 26 Oct 2005 Discontinued - Phase-II/III for Atherosclerosis in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top